Bioengineers imagine the future of vaccines and immunotherapy

December 14, 2017

In the not-too-distant future, nanoparticles delivered to a cancer patient's immune cells might teach the cells to destroy tumors. A flu vaccine might look and feel like applying a small, round Band-Aid to your skin.

These are examples of how innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts appears December 14 in the journal Trends in Immunology.

Bioengineer Christopher Jewell (@JewellBioe) and transplant surgeon and immunologist Jonathan Bromberg, both at the University of Maryland, teamed up to highlight the potential uses of proteins, lipids and polymer particles as new and improved delivery carriers in vaccines and immunotherapies.

"This is a brand-new way of thinking about how, where and when to deliver immune signals and antigens so you get a much better immune response," says Bromberg, professor of surgery and microbiology and immunology at the University of Maryland's medical school and co-senior author. "It's allowing some real paradigm shifts in thinking about vaccines for treating and preventing infectious disease, and also for potential vaccines for cancer."

In cancer, strategies include modifying specialized immune cells--T cells--with nanoparticles that provide a blueprint for destroying cancerous cells. In autoimmune diseases such as multiple sclerosis, researchers are exploring ways to use polymer particles carrying specific combinations of immune signals to deactivate malfunctioning immune cells that attack healthy cells.

Jewell, associate professor in the Fischell Department of Bioengineering and co-senior author, notes that many of these ideas are still in the pre-clinical stage and will need to be weighed against existing technologies. Microneedle patches for flu vaccinations, for one, recently proved safe and effective in a human clinical trial; many who tried it preferred it to a traditional flu shot.

The patch, embedded with almost invisible needles, delivers the vaccine to immune cells just under the skin's surface with no pain, medical visits or syringes. Patches don't require refrigeration, potentially expanding the reach and safety of vaccines in developing countries. Patches also reduce the medical waste generated by syringes. And you can apply them at home.

Vaccines are usually a mixture of two critical components: the antigen, which allows the specific recognition of a microbe, and adjuvants, which activate immune cells. Biomaterials may soon deliver adjuvants that boost and lengthen vaccines' effectiveness while minimizing the amount of injected foreign material in the body. Controlled loading and release from degradable scaffolds might help eliminate the need for multiple vaccinations.

A transplant immunologist, Bromberg seeks new ways to prevent organ rejection. He's intrigued by the possibility of immunosuppressive vaccines that inhibit the immune response. Immunomodulators that modify or weaken the immune system can also reduce inflammation caused by allergies and/or autoimmune disorders in which the body's immune system attacks its own cells.

Certain biomaterials even appear to directly activate immune pathways on their own and effectively serve as both the carrier and the adjuvant. This could lead to next-generation materials that actively control the body's responses to antigens or immunotherapy.

"Now we have an opportunity to have the carrier manipulate the immune system based on the structure, providing an additional route to engineer the most effective immune response," Jewell says.
-end-
This work is supported in part by the National Science Foundation, the National Multiple Sclerosis Society, the Damon Runyon Foundation and the Juvenile Diabetes Research Foundation.

Trends in Immunology, Bookstaver et al.: "Improving vaccine and immunotherapy 1 design using biomaterials" http://www.cell.com/trends/immunology/fulltext/S1471-4906(17)30189-8

Trends in Immunology (@TrendsImmuno), published by Cell Press, is a monthly review journal that plays an essential role in monitoring advances in the various fields of immunology, bringing together developments in basic and clinical immunology in a readable and lucid form. Visit: http://www.cell.com/trends/immunology. To receive Cell Press media alerts, contact press@cell.com.

Cell Press

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.